Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 6/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10820432 | 0.95 | CDK1 (0.74) | CDK1KDM4EALDH1A1TDP1NAAA | |
| SCHEMBL19077958 | 0.85 | NAAA (0.74) | CDK1TDP1NAAA | |
| SCHEMBL26096811 | 0.85 | NAAA (0.74) | CDK1TDP1NAAA | |
| Trimethylammonium SCHEMBL29036046 | 0.85 | CDK1 (0.64) | CDK1KDM4EALDH1A1TDP1NAAA | |
| SCHEMBL11390664 | 0.83 | CDK1 (0.74) | CDK1TDP1NAAA | |
| SCHEMBL30481046 | 0.83 | CDK1 (0.58) | CDK1KDM4EALDH1A1TDP1NAAA | |
| SCHEMBL12434388 | 0.83 | CDK1 (0.68) | CDK1KDM4EALDH1A1TDP1NAAA | |
| SCHEMBL23675381 | 0.82 | CDK1 (0.76) | CDK1TDP1NAAAPTGS1P2RX1 | |
| SCHEMBL9141821 | 0.82 | CDK1 (0.71) | CDK1KDM4EALDH1A1TDP1NAAA | |
| SCHEMBL446310 | 0.81 | CDK1 (0.70) | CDK1KDM4EALDH1A1TDP1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163209-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6646162-B2 | Compounds such as 1-(3-(2-hydroxybenzoylamino)propyl)-2-pyrrolidinone; dosage forms of bioactive agents or drugs | EMISPHERE TECHNOLOGIES, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020040061-A1 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC | 2002-04-04 | — | — | US | disclosed |
| EP-1163209-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000050386-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040061-A1 | Compounds and compositions for delivering active agents | SERPINB1, ELANE, MMP8 | CDK1 2645/4885KDM4E 4605/4885ALDH1A1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.